$4.22
0.71% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US6412557083
Symbol
NURO

NeuroMetrix, Inc. Stock price

$4.22
+0.17 4.20% 1M
+0.26 6.57% 6M
+0.62 17.22% YTD
+0.25 6.30% 1Y
-52.82 92.60% 3Y
-27.70 86.78% 5Y
-4,603.78 99.91% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.03 0.71%
ISIN
US6412557083
Symbol
NURO
Sector

Key metrics

Market capitalization $8.62m
Enterprise Value $-6.07m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.90
EV/Sales (TTM) EV/Sales -1.61
P/S ratio (TTM) P/S ratio 2.29
P/B ratio (TTM) P/B ratio 0.54
Revenue growth (TTM) Revenue growth -41.41%
Revenue (TTM) Revenue $3.77m
EBIT (operating result TTM) EBIT $-8.68m
Free Cash Flow (TTM) Free Cash Flow $-6.73m
Cash position $14.83m
EPS (TTM) EPS $-4.24
Short interest 0.79%
Show more

Is NeuroMetrix, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

NeuroMetrix, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast NeuroMetrix, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast NeuroMetrix, Inc.:

Buy
100%

Financial data from NeuroMetrix, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.77 3.77
41% 41%
100%
- Direct Costs 1.60 1.60
24% 24%
42%
2.17 2.17
50% 50%
58%
- Selling and Administrative Expenses 8.41 8.41
8% 8%
223%
- Research and Development Expense 2.24 2.24
13% 13%
59%
-8.48 -8.48
40% 40%
-225%
- Depreciation and Amortization 0.20 0.20
150% 150%
5%
EBIT (Operating Income) EBIT -8.68 -8.68
41% 41%
-230%
Net Profit -7.68 -7.68
38% 38%
-204%

In millions USD.

Don't miss a Thing! We will send you all news about NeuroMetrix, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeuroMetrix, Inc. Stock News

Neutral
GlobeNewsWire
3 months ago
WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives.
Neutral
Seeking Alpha
4 months ago
NeuroMetrix, Inc. (NASDAQ:NURO ) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai Gozani - Founder and Chief Executive Officer Conference Call Participants Jarrod Cohen - JM Cohen & Company Operator Good morning, and welcome to the NeuroMetrix Second Quarter 2024 Business and Financial Update....
Neutral
GlobeNewsWire
4 months ago
WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024.

Company Profile

NeuroMetrix, Inc. is a healthcare company, which engages in the research, development, and trade of medical equipment and consumables. It offers an over-the-counter wearable therapeutic device for chronic pain, the Quell Health Cloud, DPNCheck, and pain management devices to treat chronic pain, nerve diseases, and sleep disorder. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

Head office United States
CEO Shai Gozani
Employees 26
Founded 1996
Website www.neurometrix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today